End-binding 1 protein overexpression correlates with glioblastoma progression and sensitizes to <i>Vinca</i>-alkaloids <i>in vitro</i> and <i>in vivo</i>
authors
keywords
- RADIOTHERAPY
- CHEMOTHERAPY
- PLUS ENDS
- Glioblastoma
- EB1
- Biomarker
- Vinca-alkaloid
- Microtubules
- MICROTUBULE-TARGETING AGENTS
- BETA-CATENIN/TCF PATHWAY
- PROMOTE CELLULAR GROWTH
- HEPATOCELLULAR-CARCINOMA
- MIGRATING CELLS
- GAMMA-TUBULIN
abstract
End-binding 1 protein (EB1) is a key player in the regulation of microtubule (MT) dynamics. Here, we investigated the role of EB1 in glioblastoma (GBM) tumor progression and its potential predictive role for response to Vinca-alkaloid chemotherapy. Immunohistological analysis of the 109 human GBM cases revealed that EB1 overexpression correlated with poor outcome including progression-free survival and overall survival. Downregulation of EB1 by shRNA inhibited cell migration and proliferation in vitro. Conversely, EB1 overexpression promoted them and accelerated tumor growth in orthotopically-transplanted nude mice. Furthermore, EB1 was largely overexpressed in stem-like GBM6 that display in vivo a higher tumorigenicity with a more infiltrative pattern of migration than stem-like GBM9. GBM6 showed strong and EB1-dependent migratory potential. The predictive role of EB1 in the response of GBM cells to chemotherapy was investigated. Vinflunine and vincristine increased survival of EB1-overexpressing U87 bearing mice and were more effective to inhibit cell migration and proliferation in EB1-overexpressing clones than in controls. Vinca inhibited the increase of MT growth rate and growth length induced by EB1 overexpression. Altogether, our results show that EB1 expression level has a prognostic value in GBM, and that Vinca-alkaloid chemotherapy could improve the treatment of GBM patients with EB1-overexpressing tumor.
Aix Marseille Université | All rights reserved - Legal notice